ArticleCancer chemotherapy and pharmacology2023

Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.

Noboru Yamamoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.